Hypofractionated A-RT After Chemotherapy Resulted in Locoregional Control in Pancreatic Cancer
The single-center study evaluated 119 consecutive patients with LAPC who underwent A-RT from 2016 to 2019.
Pancreatic Cancer
Contrast-Enhanced vs Conventional Endoscopic Ultrasound for Diagnosis of Pancreatic Lesions
A team of investigators sought to investigate the usefulness of contrast-enhanced harmonic ultrasound-guided fine needle aspiration/biopsy when performed with no on-site cytopathology.
Pegilodecakin Plus FOLFOX Fails to Improve Outcomes in Metastatic PDAC
SEQUOIA trial investigators compared pegilodecakin plus FOLFOX with FOLFOX alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Vitamin D and Pancreatic Cancer: is There a Link?
Vitamin D is a biomarker of interest in the pancreatic cancer setting.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
PERT Shows Promise in Unresected Pancreatic Cancer
Investigators compared the outcomes of patients who received pancreatic enzyme replacement therapy (PERT) with those who did not.
CD73 Inhibitor-Based Triplet Induces Responses in Metastatic PDAC
The ARC-8 study evaluated whether AB680, the anti-PD-1 antibody zimberelimab, and chemotherapy could improve metastatic pancreatic adenocarcinoma (PDAC) outcomes.
Neoadjuvant Urelumab Plus Nivolumab and GVAX for Reresected Pancreatic Cancer
Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
-
Loading...
-
Loading...
Next post in General Oncology
